Protein Kinase A-II in the Pathogenesis of Lupus

狼疮发病机制中的蛋白激酶 A-II

基本信息

项目摘要

Systemic lupus erythematosus (SLE) is characterized by disordered T lymphocyte signal transduction. T cells exhibit impaired protein kinase A (PKA)-catalyzed protein phosphorylation due to a profound deficiency of type I PKA (PKA-I) isozyme phosphotransferase activity. Recently, we identified a concomitant deficiency of PKA-II isozyme activity in SLE T cells. Deficient PKA-II activity is associated with (a) autophosphorylation and aberrant translocation of the beta isoform of the type II regulatory subunit (RIIbeta) from the cytosol to the nucleus; (b) accumulation and retention of nuclear RIIbeta; and, (c) reduced or undetectable c-Fos cytosolic protein. Therefore, we hypothesize that aberrant nuclear translocation of autophosphorylated RIIbeta results in (a) deficient PKA-II activity, (b) under-phosphorylation of nuclear cAMP response element binding protein (CREB) transcription factor, (c) impaired c-fos transcriptional activation, (d) reduced levels of c-fos transcript and c-Fos protein, (e) decreased formation of AP-1 transcription factor, and (f) impaired IL-2 transcriptional activation. The specific aims of this proposal are: (l) To demonstrate that autophosphorylated RIIbeta-subunit is a transcription factor that forms a RIIb-CREB heteromeric complex and acts as a transcriptional repressor of CREB-mediated c-fos transcription in normal primary T cells; (2) To identify the mechanism(s) leading to aberrant translocation of the RIIbeta-subunit from the cytosol to the nucleus in SLE T cells; (3) To determine if PKA-II-catalyzed phosphorylation of CREB is impaired and hinders its binding to CREB binding protein (CBP) and transcriptional activation of the c-Fos promoter in SLE T cells; and, (4) To determine if there is diminished AP-1 binding to consensus AP-1 sites of the IL-2 promoter/enhancer that results in reduced IL-2 production in SLE T cells. The principal goal of the proposed experiments is to establish the mechanism(s) by which deficient PKA-II isozyme activity contributes to altered c-Fos and IL-2 transcriptional activation, loss of AP-1, and diminished IL-2 production by SLE T cells. Demonstrating a connection between reduced T cell IL-2 production and deficient PKA-II isozyme activity in SLE T cells will address a principal gap in our understanding of the molecular and cellular pathophysiology of T cell immunodysfunctions in SLE.
全身性红斑狼疮(SLE)的特征是T淋巴细胞信号转导。 T细胞表现出受损的蛋白激酶A(PKA)催化的蛋白磷酸化,这是由于I型PKA(PKA-I)同工酶磷酸转移酶活性的严重缺陷。最近,我们确定了SLE T细胞中PKA-II同工酶活性的伴随缺乏。缺乏PKA-II活性与(a)II型调节亚基(Riibeta)从细胞质到细胞核的II型调节亚基(Riibeta)的β同工型的自磷酸化和异常易位有关; (b)核riibeta的积累和保留; (c)降低或无法检测到的C-FOS胞质蛋白。因此,我们假设自磷酸化的riibeta的异常核易位导致(a)核营地响应蛋白(CREB)转录因子(CREB)转录因子(C)C-FOS转录率的降低,(D)降低了C-FOS的pROS-FOS蛋白质(e-FOS)的水平,(e (f)IL-2转录激活受损。该提案的具体目的是:(l)证明自磷酸化的riibeta-subunit是一种转录因子,形成了RIIB-CREB异质体复合物,并充当正常主要T细胞中CREB介导的C-FOS转录的转录抑制剂; (2)确定导致riibeta-subunit异常易位的机制,从细胞质到SLE T细胞中的细胞核; (3)确定CREB的PKA-II催化磷酸化是否受到损害,并阻碍其与CREB结合蛋白(CBP)的结合以及C-FOS启动子在SLE T细胞中的转录激活; (4)确定与IL-2启动子/增强子的共有AP-1位点的AP-1结合减少,从而导致SLE T细胞中IL-2产生降低。提出的实验的主要目标是建立缺乏PKA-II同工酶活性有助于改变C-FOS和IL-2转录激活,AP-1的丢失以及SLE T细胞产生IL-2的机制。证明SLE T细胞中T细胞IL-2的产生减少与缺乏PKA-II同工酶活性之间的联系将解决我们对SLE中T细胞免疫功能的分子和细胞病理生理学的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

ELIZABETH HILTBOLD...的其他基金

Impact of bacterial infection on myeloid dendritic cell development
细菌感染对骨髓树突状细胞发育的影响
  • 批准号:
    8575047
    8575047
  • 财政年份:
    2013
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:
Mechanisms of Listeria-Specific Immunity
李斯特菌特异性免疫机制
  • 批准号:
    7339634
    7339634
  • 财政年份:
    2005
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:
Mechanisms of Listeria-Specific Immunity
李斯特菌特异性免疫机制
  • 批准号:
    7560374
    7560374
  • 财政年份:
    2005
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:
Mechanisms of Listeria-Specific Immunity
李斯特菌特异性免疫机制
  • 批准号:
    7174779
    7174779
  • 财政年份:
    2005
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:
Mechanisms of Listeria-Specific Immunity
李斯特菌特异性免疫机制
  • 批准号:
    6866292
    6866292
  • 财政年份:
    2005
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:
Mechanisms of Listeria-Specific Immunity
李斯特菌特异性免疫机制
  • 批准号:
    7447978
    7447978
  • 财政年份:
    2005
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:
Mechanisms of Listeria-Specific Immunity
李斯特菌特异性免疫机制
  • 批准号:
    7013151
    7013151
  • 财政年份:
    2005
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:
Protein Kinase A-II in the Pathogenesis of Lupus
狼疮发病机制中的蛋白激酶 A-II
  • 批准号:
    6852715
    6852715
  • 财政年份:
    2001
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:

相似海外基金

Protein Kinase A-II in the Pathogenesis of Lupus
狼疮发病机制中的蛋白激酶 A-II
  • 批准号:
    6632185
    6632185
  • 财政年份:
    2001
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:
Protein Kinase A-II in the Pathogenesis of Lupus
狼疮发病机制中的蛋白激酶 A-II
  • 批准号:
    6852715
    6852715
  • 财政年份:
    2001
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:
Protein Kinase A-II in the Pathogenesis of Lupus
狼疮发病机制中的蛋白激酶 A-II
  • 批准号:
    6327266
    6327266
  • 财政年份:
    2001
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:
Protein Kinase A-II in the Pathogenesis of Lupus
狼疮发病机制中的蛋白激酶 A-II
  • 批准号:
    6511161
    6511161
  • 财政年份:
    2001
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别:
EPSTEIN BARR VIRUS LMP1 MEDIATED ONCOGENICITY
Epstein Barr 病毒 LMP1 介导的致癌性
  • 批准号:
    6776477
    6776477
  • 财政年份:
    2000
  • 资助金额:
    $ 25.2万
    $ 25.2万
  • 项目类别: